In the Boardroom - Forest Laboratories, Cardio-vascular

Filter

Popular Filters

1 to 25 of 680 results

Heart Metabolics raises $20 million for Phase III heart disease drug trial

17-04-2014

Irish biotech company Heart Metabolics has completed a $20 million round of financing to support its…

BiotechnologyCardio-metabolic diseasesCardio-vascularDrug discoveryFinancialHeart diseaseHeart Metabolics LimitedIrelandPeter Milner

Astellas US promotes Jeffrey Bloss to SVP of medical affairs for the Americas

Astellas US promotes Jeffrey Bloss to SVP of medical affairs for the Americas

16-04-2014

The US subsidiary of Japanese drug major Astellas Pharma announced that Jeffrey Bloss has been promoted…

Astellas PharmaBoardroomManagementPharmaceuticalUSA

Pharmacovigilance Risk Assessment Committee April meeting highlights

Pharmacovigilance Risk Assessment Committee April meeting highlights

11-04-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) gave a recommendation…

Cardio-vascularEuropeMen's HealthNeurologicalPharmaceuticalRegulationRespiratory and Pulmonary

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

Forest and Almirall get FDA feedback on fixed dose combo of aclidinium and formoterol

09-04-2014

US drugmaker Forest Laboratories and partner Almirall, Spain’s largest pharma company, say they have…

aclidiniumAlmirallForest LaboratoriesformoterolNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryUSA

JPMA sanctions against Takeda over promotional activities for candesartan in Japan

09-04-2014

Japan’s largest drugmaker Takeda Pharmaceutical says it has received notice of sanctions imposed by…

Asia-PacificBlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalTakeda Pharmaceuticals

Teva launches first generic Lovaza in USA

Teva launches first generic Lovaza in USA

08-04-2014

Israel-based Teva Pharmaceutical Industries says it has received US Food and Drug Administration approval…

Cardio-vascularGenericsGlaxoSmithKlineLovazaMarkets & MarketingRegulationTeva Pharmaceutical IndustriesUSA

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

US FDA clears Boehringer Ingelheim’s Pradaxa for additional indications

07-04-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimCardio-vascularNorth AmericaPharmaceuticalPradaxaRegulationUSA

New Haven Pharmaceuticals appoints Larry Dillaha as Executive Vice President Operations

New Haven Pharmaceuticals appoints Larry Dillaha as Executive Vice President Operations

02-04-2014

New Haven Pharmaceuticals, a privately held specialty pharmaceuticals company, today announced the appointment…

BoardroomNew Haven PharmaceuticalsPharmaceuticalUSA

Amarin and Kowa Pharma to co-promote Vascepa in USA

01-04-2014

US biotech firm Amarin Corp and Kowa Pharmaceuticals America, owned by Japan’s Kowa, have reached an…

AmarinBiotechnologyCardio-vascularKowa PharmaceuticalsMarkets & MarketingNorth AmericaUSAVascepa

Paul Sekhri joins Sanofi as Senior Vice President

Paul Sekhri joins Sanofi as Senior Vice President

01-04-2014

Paul Sekhri has joined French drug major Sanofi as Senior Vice President, Integrated Care effective…

BiotechnologyBoardroomPharmaceuticalSanofiUSA

Inovio Pharmaceuticals appoints EJ Brandreth as vice president of quality

Inovio Pharmaceuticals appoints EJ Brandreth as vice president of quality

01-04-2014

USA-based Inovio Pharmaceuticals (NYSE MKT: INO) has announced the appointment of EJ Brandreth as Vice…

BoardroomInovio PharmaceuticalsPharmaceuticalUSA

Par Pharmaceutical appoints Terrance Coughlin as chief operating officer

Par Pharmaceutical appoints Terrance Coughlin as chief operating officer

01-04-2014

Par Pharmaceutical Companies (NYSE: PRX) has announced the appointment of Terrance Coughlin as chief…

BoardroomPar PharmaceuticalPar PharmaceuticalsPharmaceuticalUSA

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

01-04-2014

German drug major Bayer presented new analyses from the pivotal ROCKET AF and EINSTEIN clinical trials…

BayerCardio-vascularJohnson & JohnsonPharmaceuticalResearchXarelto

Novartis halts Ph III LCZ696 trial on strong results

Novartis halts Ph III LCZ696 trial on strong results

31-03-2014

Swiss drug major Novartis says that the Data Monitoring Committee (DMC) unanimously recommended early…

Cardio-vascularLCZ696NovartisPharmaceuticalResearch

Sanofi appoints Dr Anne Beal as chief patient officer

Sanofi appoints Dr Anne Beal as chief patient officer

31-03-2014

French drug major Sanofi has announced the appointment of Anne Beal to the newly created position of…

BiotechnologyBoardroomFrancePharmaceuticalSanofiUSA

aTyr Pharma appoints David Weiner as Chief Medical Officer

aTyr Pharma appoints David Weiner as Chief Medical Officer

31-03-2014

aTyr Pharma, a rare disease biotherapeutics enterprise, has announced the appointment of David Weiner…

aTyrBiotechnologyBoardroomUSA

ACC 2014: GSK’s darapladib disappoints in Ph III trial

ACC 2014: GSK’s darapladib disappoints in Ph III trial

31-03-2014

UK pharma major GlaxoSmithKline (LSE: GSK) presented disappointing data from its pivotal Phase III STABILITY…

Cardio-vasculardarapladibGlaxoSmithKlinePharmaceuticalResearchUKUSA

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

ACC 2014: Amgen’s evolocumab reduces cholesterol by up to 66%

31-03-2014

USA-based Amgen announced data at the American College of Cardiology 63rd Annual Scientific Session this…

AmgenBiotechnologyCardio-vascularevolocumabResearchUSA

US FDA advisory panel votes against approval of Novartis’ AHF drug

US FDA advisory panel votes against approval of Novartis’ AHF drug

28-03-2014

The US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee yesterday voted…

Cardio-vascularNorth AmericaNovartisPharmaceuticalReasanzRegulationserelaxinUSA

Glenmark gets $4 million milestone in Forest collaboration

Glenmark gets $4 million milestone in Forest collaboration

27-03-2014

Indian drugmaker Glenmark Pharmaceuticals has informed the Stock Exchange today that the company through…

FinancialForest LaboratoriesGlenmark PharmaceuticalsInflammatory diseasesLicensingPharmaceutical

Adaptimmune announces appointment of James Noble as Chief Executive Officer

Adaptimmune announces appointment of James Noble as Chief Executive Officer

26-03-2014

Adaptimmune, a biotech company focused on the use of engineered T cells to treat cancer, has announced…

AdaptimmuneBiotechnologyBoardroomImmunocoreUK

Merck promotes internal top managers to head Merck Millipore and Consumer Health Divisions

Merck promotes internal top managers to head Merck Millipore and Consumer Health Divisions

26-03-2014

German pharma and chemical major Merck KGaA has announced the promotion of three distinguished internal…

AllergopharmaBiotechnologyBoardroomGermanyMerck KGaAPharmaceutical

Angle appointments new Scientific Adviser

Angle appointments new Scientific Adviser

26-03-2014

Angle (AIM:AGL), the specialist medtech company, has appointed Clive Stanway as a Scientific Adviser…

AngleBiotechnologyBoardroomCancer Research TechnologyOncologyUK

Lupin launches generic Niaspan in USA

24-03-2014

Indian drugmaker Lupin says that its US subsidiary has launched its niacin extended-release tablets USP,…

AbbVieCardio-vascularGenericsLupinMarkets & MarketingNiaspanNorth AmericaUSA

1 to 25 of 680 results

Back to top